Topics
CNS Tumors | Treatment | Targeted therapy | Defactinib
Home > Publications > Topics > CNS Tumors > Treatment > Targeted therapy > Defactinib
Zauderer MG, Jegede O, Jackman DM, Zwiebel JA, Gray RJ, Wang V,
McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR,
Takebe N, Huang R, Carrillo JA, Brenner AJ, Tricoli JV, Conley BA,
Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.
Phase
II Study of Defactinib (VS6063) in Patients With Tumors
With NF2
Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131)
Subprotocol U.
JCO
Precis Oncol. 2024 Dec 18;8:e2400327. doi:
10.1200/PO.24.00327. PMID:
39693587. Interventional study˰
ˍ